Big Data Analysis of Genes Associated With Neuropsychiatric Disorders in an Alzheimer’s Disease Animal Model

Abstract

Alzheimer’s disease is a neurodegenerative disease characterized by the impairment of cognitive function and loss of memory, affecting millions of individuals worldwide. With the dramatic increase in the prevalence of Alzheimer’s disease, it is expected to impose extensive public health and economic burden. However, this burden is particularly heavy on the caregivers of Alzheimer’s disease patients eliciting neuropsychiatric symptoms that include mood swings, hallucinations, and depression. Interestingly, these neuropsychiatric symptoms are shared across symptoms of bipolar disorder, schizophrenia, and major depression disorder. Despite the similarities in symptomatology, comorbidities of Alzheimer’s disease and these neuropsychiatric disorders have not been studied in the Alzheimer’s disease model. Here, we explore the comprehensive changes in gene expression of genes that are associated with bipolar disorder, schizophrenia, and major depression disorder through the microarray of an Alzheimer’s disease animal model, the forebrain specific PSEN double knockout mouse. To analyze the genes related with these three neuropsychiatric disorders within the scope of our microarray data, we used selected 1207 of a total of 45,037 genes that satisfied our selection criteria. These genes were selected on the basis of 14 Gene Ontology terms significantly relevant with the three disorders which were identified by previous research conducted by the Psychiatric Genomics Consortium. Our study revealed that the forebrain specific deletion of Alzheimer’s disease genes can significantly alter neuropsychiatric disorder associated genes. Most importantly, most of these significantly altered genes were found to be involved with schizophrenia. Taken together, we suggest that the synaptic dysfunction by mutation of Alzheimer’s disease genes can lead to the manifestation of not only memory loss and impairments in cognition, but also neuropsychiatric symptoms.

Two-sample Mendelian randomization analysis of 91 circulating inflammatory protein levels and amyotrophic lateral sclerosis

“…It highlights the diverse roles of cytokines, including LIFR, in skeletal muscle physiology and their impact on muscle cell growth, differentiation, metabolism, nerve innervation, and inflammatory cell recruitment to muscle injury sites ( Hunt and White, 2016 ). The research also touches on the limited but emerging findings linking AIFR and Osteoprotegerin to ALS, as well as their roles in neuropsychiatric disorders, emphasizing the importance of inflammation and immune mechanisms in these conditions ( Ham et al, 2018 ; Hashioka et al, 2019 ; Novellino et al, 2020 ; Xu et al, 2023 ).…”

Whole-genome sequencing analysis of suicide deaths integrating brain-regulatory eQTLs data to identify risk loci and genes

“…Our Sherlock integrative analysis found 20 genes where expression changes may contribute to suicide risk, with nine of these genes having evidence of differential expression in psychiatric conditions, including schizophrenia (SCZ), autism spectrum disorder (ASD), depression, stress response, and neurodegeneration. Specifically, findings implicated variants associated with overexpression of SCZ-associated genes: SNX19 [ 55 – 58 ], CNN3 [ 59 , 60 ], BCAP29 (opposite direction of prior findings [ 61 ]), and IGF1R (opposite direction of prior findings [ 62 ]). ZNF501 was found to have diminished expression with the associated variant in this study, consistent with prior ASD [ 63 ] and depression studies [ 64 ].…”

Target Genes of Autism Risk Loci in Brain Frontal Cortex

“…In addition, HIST1H1C may also be involved in other brain disease development. For example, HIST1H1C displayed consistently significant increased mRNA level in the cortex of brains from 7- and 18-month-old mice in an Alzheimer’s disease model (Ham et al, 2018). The mRNA level of HIST1H1C is up-regulated in hypoxia and is correlated with worse disease outcome among neuroblastoma patients (Applebaum et al, 2016).…”